Tandem Diabetes Care, Inc. (TNDM) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Susan Morrison
executiveGood afternoon, and welcome to Tandem's earnings call for the third quarter of 2026. Remarks today will contain forward-looking statements — among them statements regarding our CEO transition and when it will occur, our leadership, our strategy, our product pipeline, development timelines, and financial performance, profitability included, plus our operating plans — and those statements speak only as of today's date. They reflect what we currently expect regarding future events and carry risks and uncertainties that might make actual results differ materially from what our forward-looking statements anticipate or project; those risks and uncertainties are described in the press release we issued earlier today, in the Risk Factors section of our latest annual report on Form 10-K and quarterly report on Form 10-Q, and in the Form 8-K we issued today. References to both GAAP and non-GAAP financial measures will also come up on today's discussion. For a reconciliation of non-GAAP measures to the most directly comparable GAAP financial measure, and for other information about how we use non-GAAP financial measures, please see our earnings release issued today, which is available on the Investor Center portion of our website. Additionally, this afternoon we issued a press release on the planned evolution of Tandem's CEO leadership. To speak to that announcement, the chair of Tandem's Board of Directors, Beckie Robertson, is joining us to open today's call. We'll then hear our third quarter earning results and a company update from John Sheridan, President and CEO, and Leigh Vosseller, Executive Vice President and Chief Financial Officer. Once their prepared remarks are done, we'll open the call for questions with John and Leigh. Thank you in advance for limiting yourself to one question before rejoining the queue. I'll now turn the call over to Beckie.
Beckie Robertson
executiveThank you, Susan, and hello everyone this afternoon. Today's announcement about leadership succession marks an important step forward for Tandem Diabetes Care. It's a transition we had planned, and alongside it we're honoring John Sheridan's impressive run as he prepares to step down and retire at the close of 2026, while also expressing our enthusiasm about Jeanette Bankes becoming Tandem's next President and CEO. On behalf of the board, I'd like to voice our gratitude to John for over ten years of dedication to Tandem, eight of which he spent as CEO. Under John's guidance, Tandem has grown into a worldwide innovator in diabetes care. He brought Control-IQ to market—our first hybrid closed-loop technology—advanced our digital health strategy, and expanded the portfolio with the introduction of Mobi. On top of that, he prepared the ground for Tandem to operate at scale internationally and got business model changes underway that broaden customer access. Just as important, he established a culture driven by mission that will continue to shape this company. With that foundation in place, Jeanette is the right leader to guide Tandem through its next phase of growth. Jeanette emerged as the standout during the board's succession planning and search process, bringing over 30 years of global operating experience and a strong track record of turning strategy into consistent execution and growth. Given her track record growing medtech companies, she fits Tandem nicely at this point, as we take advantage of our updated business model and push into global markets. Jeanette's focus on customers, wide-ranging viewpoint, and dedication to innovation align tightly with Tandem's culture, mission, and priorities while we move our technology roadmap forward, broaden customer access, and chase sustainable growth and profitability. She is likewise well-suited to help shape Tandem's long-term strategy and bolster our competitive standing. During the transition, our leadership team remains focused on Tandem's strategic priorities, and the board trusts the organization's ability to deliver. John, thanks again for your leadership and your dedication to Tandem. Jeanette, we're thrilled to welcome you to the company on November 16th. With that, I'll hand the call over to John.
John Sheridan
executiveThanks, Beckie, and good morning, everyone — welcome to the call today. Working alongside such an amazing team of employees and the board since 2013 has been a privilege, and I've been honored to lead this company over the last eight years. Together, we moved Tandem's mission forward — improving the lives of people living with diabetes. I'm proud of all that we've accomplished, especially that 500,000 people around the world now benefit from Tandem's technology. Tandem's fundamentals remain strong, and I have full confidence in its future with Jeanette at the helm. She has the experience, the perspective, and the dedication required to build on our momentum, and I look forward to supporting her through a smooth transition. Our team is still focused on carrying out our strategy and creating value for customers and shareholders; with that in mind, let's go over our earnings results and the progress we're making across the business. Looking back at the third quarter and how we've performed so far this year, I'm proud of what Tandem has achieved in 2026; we're executing our strategic priorities to broaden access to Tandem's life-changing technology, while reinforcing our business model, moving our pipeline forward, and driving efficiency in our operations. These efforts are producing tangible results; we beat expectations across the P&L, with greater contribution from our US pharmacy transition and the international shift to direct operations. Q3 was also a quarter of record sales and pump shipments, with both increasing double digits worldwide. Higher pricing helped, along with US new pump starts returning to year-over-year growth, plus strong early demand for Tandem Mobi across the 12 countries where it is now sold internationally. Alongside top-line growth, we are achieving substantial margin expansion. That comes from focused execution on our efficiency initiatives and from balancing cost discipline with investment in growth. These recent accomplishments give us a solid foundation that positions Tandem for long-term success. Today we will provide more color on these results and review progress against our strategic priorities. Beginning with reshaping our business model, we are making major shifts in how we approach the global markets. In the US, pharmacy sales now account for 15% of US sales, just two full quarters into the pay-go reimbursement model. Throughout the year we've been steadily widening access, and we've already hit the top end of our full-year target, with formulary coverage at roughly 50%. Early pharmacy results show the model is putting us in position to reach our goals — getting to more people through simplified access with lower upfront costs, while generating greater economic benefit for our business. Outside the United States, earlier in the year we began direct commercial operations in the UK, Switzerland, and Austria, and we remain on track to do the same in France this week. France ranks among our bigger European markets, so it marks a significant next step in our international strategy. Adding it means over 30% of our international installed base will be served directly. We intend to continue expanding our direct operations across 2027, and by the end of next year our footprint will reach about 0.5 million — roughly half of that installed base. Results from direct international operations in 2026 so far confirm the model's strategic worth, because we form closer ties with customers and healthcare providers and capture greater economic value. Turning to pipeline updates: we believe Tandem Mobi Tubeless has reached the late stages of FDA review. Mobi Tubeless is designed to be the first and only tubeless AID system globally, offering up to seven days of wear. This additional infusion site choice converts a current Mobi pump into a tubeless setup. Using the same rechargeable pump, people can switch between tubed and tubeless use just by changing their supplies. Combining Control-IQ's top-tier A1C results with tubeless wear positions Tandem to compete in the pump market's fastest-growing segment, providing more wear options than any competing system. After receiving clearance, we plan to begin a scaled commercial launch, increase manufacturing capacity, and revise pharmacy contracts. We're excited as well about bringing Mobi Tubeless to healthcare providers, and assuming clearance comes through, we're preparing to begin limited customer use before moving to full commercial availability during the first half of 2027. To shorten the path to market, our first submission centered on abdominal wear, and we'll work alongside the FDA to add additional wear locations and insulin types. Innovation also keeps moving forward throughout the remainder of our portfolio. Infusion set technology stays a major priority as we strive to boost comfort, lengthen wear time, cut down on occlusions, and make the user experience simpler. During the third quarter, we kicked off a worldwide rollout of AutoSoft Plus, a fresh infusion set sourced from an outside vendor that’s built to make handling simpler through dependable single-handed insertion. AutoSoft Plus has reached certain markets at this point, and assuming local regulatory clearances come through, our intention is to move into further regions during the opening part of 2027. That schedule is significant given that we’re still coping with vendor shortfalls on additional infusion sets; availability of supply got better in Q3, and although conditions keep improving, a degree of strain persists through the start of 2027. We're also preparing to introduce SteadiSet after Mobi Tubeless, which is our own proprietary technology and has FDA clearance for as many as seven days of wear, giving customers more infusion set options; during Q3 we made significant progress as well on advancing our automated insulin delivery work. From the start, our vision has rested on pursuing an algorithm that truly deserves to be called an artificial pancreas. During our previous call, we noted that Tandem has never been this close to reaching that goal. Extending the research collaboration we've had with the University of Virginia for a long time, Tandem has taken UVA's next-generation AID algorithm and turned it into a completely closed-loop system. This system aims to assist individuals managing type 1 and type 2 diabetes in hitting clinical time-in-range goals without needing meal announcements or any other inputs, while still permitting users to add extra details for a more tailored experience. We continue driving ahead on the necessary work so that a pivotal study can begin before 2026 ends, which will back a submission to the FDA. Having said that, I'll pass things to Leigh, who will cover more specifics on our third-quarter financial performance.
Leigh Vosseller
executiveThanks, John. As John laid out, the results for our third quarter show we made considerable headway throughout the business. We set numerous new Q3 records in sales, pump shipments, and gross margin. On the whole, the quarter offered more proof that our strategy and our business model initiatives are producing meaningful results. My remarks today will center on the main drivers behind our performance and on what they signal regarding the company's financial trajectory. Beginning with sales, worldwide revenue rose 14% year-over-year to $284 million. Pump shipments were up 12%, to roughly 33,000 pumps. Within the US, pump shipments climbed 11% year-over-year to almost 23,000. The trend in new customer starts kept improving and came back to growth during the quarter. MDI conversions accounted for about 70% of new customers, and renewals posted a double-digit growth rate. Taken together, these results strengthen our confidence that product innovation, changes to our business model, and commercial investments are growing the insulin pump market. US sales rose 9% year-over-year to $191 million, fueled by greater pump demand, pharmacy pricing, and pharmacy adoption. The pay-go model is still a substantial opportunity for our business, and we raised every one of our key pharmacy metrics this quarter. Pharmacy grew a lot, hitting 15% of US sales during Q3; in addition, we reached our access target for the year earlier than planned, with about 50% of US covered lives now on formulary, and we anticipate Mobi Tubeless will act as a major driver of additional expansion. Even though the $0 pump under our pay-go model causes an initial revenue headwind, greater recurring supply revenue more than compensated for it this quarter, with net supply ASPs again exceeding $350 per month, above our baseline expectations. Pharmacy penetration climbed to roughly 12% of pump shipments and 7% of our ordering installed base. Adoption keeps scaling, despite the transition moving more slowly than we originally expected. That speed mostly shows how long it takes to build new prescription processes and shift habits among our teams, healthcare providers, and customers. Since launch, the count of healthcare providers prescribing through pharmacy has climbed each month, and we think new pharmacy-exclusive products, including Mobi Tubeless and AutoSoft Plus, will help accelerate uptake. During the fourth quarter, we anticipate shipping roughly 15% to 20% of pumps and 8% to 10% of installed base supplies via pharmacy, which equals almost 15% of US sales. Because pump adoption through pharmacy is moving faster than supply conversions, we expect sales headwinds to persist into 2027. Crucially, the fundamental metrics continue to improve, among them formulary access, provider participation, and recurring supply economics. We're eager to demonstrate the capabilities of this model at larger scale throughout our substantial and expanding installed base of close to 330,000 customers. Moving on to how we performed internationally, we shipped nearly 11,000 pumps and posted our strongest sales quarter to date at $93 million — a 26% increase year-over-year, or 27% on a constant currency basis. New product introductions and solid execution in our direct markets largely drove these results, together with the expected lift from supply orders that had been pushed out of the second quarter. We're also beginning to realize the benefits of our shift to direct operations, as direct market shipments rose 30% sequentially with considerably improved pricing. Direct channel sales made up roughly 18% of international revenue for the quarter and 14% year-to-date, which keeps us on track for the full-year expectation of 15%. The quarter also carried a $3 million headwind from our direct market transitions, taking the year-to-date impact to about $7 million out of the $15 million we expect for the full year. Moving to margins, the steps we've taken to strengthen our margin profile are producing results. Gross margin came in at 57%, up nearly 3 percentage points year-over-year. That performance largely reflects better pricing from our global business model changes. Supply margins hit an all-time high, climbing over 10 percentage points during the past two years, and we continue to benefit from cheaper product costs as Mobi gains traction in the market. For the quarter, operating expenses came to $163 million, only 4% higher than a year earlier, since we maintained strict cost discipline even while funding our strategic growth priorities. SG&A increased on the strength of commercial investments around the world, whereas R&D held steady; a $5 million drop in stock-based compensation expense largely offset those increases; because revenue grew much faster than expenses, we produced substantial operating leverage, lifting operating margin by 8 percentage points and adjusted EBITDA margin by 5 percentage points. Adjusted EBITDA represented 6% of sales, which made it our fifth quarter in a row of positive adjusted EBITDA. We ended the quarter with a solid balance sheet: $443 million in cash and investments. Free cash flow showed ongoing spending to rebuild infusion set inventory up to the stocking levels we want, plus additional capital equipment investment to back upcoming product launches. As for our 2026 expectations, we feel encouraged by the significant progress we're making in the global transformation of our business model. Results so far this year strengthen our confidence in the 2026 guidance. We expect worldwide sales to fall between $1,065 million and $1,085 million. Within that, US revenue should land between $730 million and $745 million, while markets outside the US are expected to bring in $335 million to $340 million. Gross margins are projected at 56% to 57%, with adjusted EBITDA margin coming in at 5% to 6% of annual sales. To wrap up, I'm proud of how we executed this year and the solid third-quarter results we posted. Those results strengthen our confidence in the business's financial path and in our 2026 outlook. With that, I'll hand the call back to John.
John Sheridan
executiveThanks, Leigh. To wrap up, the results we delivered in the third quarter show strong execution on the priorities we laid out for this year, and they strengthen my confidence in where Tandem is headed strategically. We're taking real momentum into the last months of 2026, with our attention squarely on broadening customer access, pushing innovation forward, and generating sustainable, profitable growth. Before I finish, I'd like to thank everyone across the Tandem team. Your dedication, resilience, and commitment to our customers are what made this progress happen, and I'm profoundly grateful for all that you do for Tandem and for the diabetes community we serve. With that, I'll hand the call to the operator for questions.
Mathew Blackman
analystGood afternoon to all of you. Is the audio coming through clearly for everyone?
John Sheridan
executiveYes, we can hear you.
Mathew Blackman
analystGreat. John, congratulations, and best of luck in whatever comes next. I'm just wondering why now feels like the right moment for you to step aside. A lot has clearly been achieved over the past couple of years, but you're also right on the edge of some very exciting developments. I'd just like your thinking on why now, and what the business looks like as you move on. Any thoughts you have would be really helpful. Thank you.
John Sheridan
executiveSure. I'm no spring chicken anymore. I'm 70 years old. I know I look like 60, but I'm 70, and at some point I've got to make a decision. I've been working with the board for quite a while now. The things I really cared about getting accomplished before I stepped down were Mobi Tubeless, the pharmacy channel, the OUS expansion, and certainly the fully closed-loop systems. As we enter 2026, I feel very confident that these things are moving in the right direction, that we're going to execute, and with a great deal of confidence. The second thing you've got to do then is find somebody to replace me, and we've done a lot of searching on this, and we found an outstanding candidate in Jeanette Bankes. She's got great experience as a leader of multiple medical technology companies for many years. More importantly, she's got, I'd say, the kind of cultural awareness that's really important to our business, since she is very mission-driven. She's capable, she's got a track record of executing on strategy. I think she's going to do a great job, and I look forward to supporting her over the next couple of months. It's really just a matter of there being some things I wanted to get done. I really feel confident that these things are going to get done, and we've got a great leader in Jeanette. I am rooting for the company as we go on into 2027 and beyond.
Mathew Blackman
analystAll right, thanks. I'll get back in line.
Matthew O'Brien
analystHello, and I appreciate you taking my question this afternoon. John, let me join Matt in wishing you a happy retirement—best of luck. I could use some more color on the pharmacy channel. Given how many calls there are tonight, I may have missed something, but a 15% figure in Q3 would, as I figure it, require 29% in Q4 for the year to average out at 15%, and that seems unlikely to me. How are we now thinking about pharmacy revenue for the full year '26, and then how should we view that metric as we go through all of '27? Many thanks.
Leigh Vosseller
executiveYes. That's a good question, Matt. That's quite a bit to address. To begin, I'll take the broadest view and walk through what I'd call the three main levers showing how we're doing in pharmacy. Let me begin with access: we've now gotten to roughly 50% coverage on formulary, which is significantly better than we had anticipated, and at this early point that matters most because it creates the opportunity ahead of us. The second lever is pricing, and here I'd note that we're comfortably beating the baseline assumption we established of $350 per month — in fact, the average is currently nearer $400. At this point we'd like everyone to keep their expectations in check, since we only have two quarters' worth of data. New contracts keep coming in, and the volume remains quite small — we want to watch how things develop over a longer horizon — but performance on that front has been very strong. The third progress measure is adoption pace, and there I'd say things have been moving along somewhat more slowly than we initially expected. Looking forward, it's rising quarter by quarter, and we anticipate another rise in the fourth quarter; however, the original assumptions we shared at the start of the year will not be met. Having gathered two quarters' worth of data, we now feel we can approach the road ahead with a clearer perspective. Our confidence remains strong that we will deliver on the targets we laid out for the two- to three-year horizon — specifically, that by the close of '28 this model will have been flipped, with pharmacy accounting for nearly everything and DME making up only a small remainder. That effort is progressing as it should. You've raised a genuinely important point: what comes next? As we plan for the year, our current assumptions put pay-go pumps at roughly 10% to 12%. If you look at pharmacy as a share of sales, the average will likely land a bit higher in the low teens—say 10% to 12% as well. That simply reflects the more gradual pacing we've been seeing, and we're taking into account that adoption of the pharmacy pump has been moving a little faster than conversion of the supply base. That carries us into 2027, when we think the headwinds we've discussed may roll into the following year. Given the new information on pacing that we now have and have shared today, I'd expect people will need to revisit their models for next year and recalibrate them for this new information.
Kieran Ryan
analystHello. Appreciate you taking my question, and congratulations to John. I'd like to ask about Tubeless Mobi and the commentary and timing you provided on that. Regarding commercial availability in the first half of '27, could you speak to how much of your existing pharmacy formulary coverage you'd anticipate being live for Tubeless Mobi by then, and whether plans would cover it through existing Mobi arrangements or whether that would be handled plan by plan? And then, on a similar note, I'm curious how a current Mobi user who gets access through DME might be able to access Tubeless Mobi. Thank you.
Leigh Vosseller
executiveCertainly. I'll field that one, actually. That 50% coverage we have today serves as the starting point for Mobi Tubeless; we're in further discussions right now, and we anticipate continuing to expand that coverage by the time full commercial availability arrives; as a matter of fact, Mobi Tubeless and AutoSoft Plus, being pharmacy-only products, are truly a key driver for bringing more throughput into the pharmacy channel, and they can accelerate that pace of adoption for us. Mobi Tubeless itself is also a significant discussion point with the PBMs and the payers, since they see this as very important to what they want in the pharmacy channel and far more directly competitive with the other tubeless option out there. Coverage begins where we stand today already, and we expect to keep building on it over the course of the year.
John Sheridan
executiveKieran, suppose you already own a Mobi pump right now — then the only thing you’d truly need is to purchase the tubeless supplies. What you get is an infusion plate plus a cartridge built to pair with that infusion plate. Switching over from a tubed Mobi to a tubeless Mobi is really straightforward. Our expectation is that folks within the current installed base will be eager to make that move quickly once the product reaches the market.
Larry Biegelsen
analystHi there, this is Larry, and I appreciate you taking my question. So I suppose, John, regarding Mobi Tubeless — and incidentally, congratulations; honestly, I truly believed you'd keep going until age 80, though apparently that's not the case.
John Sheridan
executiveThank you, Larry.
Larry Biegelsen
analystHi there, so do you anticipate getting clearance during Q4, and what exactly makes you confident that you're now at a late stage in the review? Also, why is it abdominal wear only, and what would the pathway be for securing other sites such as the arm, and how do you figure that restricts commercial uptake if abdominal wear is all that's available? Thanks.
John Sheridan
executiveMy view is that once you begin working with FDA on filings like these, questions come up, and as you near the finish line those questions shift, and they become much more about getting ready to launch. Right now we are clearly in that stage with them, and I believe our expectation is approval in the fourth quarter. Beyond that, regarding the way we submitted this, we filed in a manner designed to move through review quickly, but along the way we engage with the FDA, and we inform them of our plans to make these changes, and they have mechanisms that let us reach agreement in advance that such changes may be made, and we specify the test protocols plus the results we would anticipate hitting, and we're able to keep doing that once clearance has been received. This product will be launched with multiple locations as well as multiple insulins, and we believe we can accomplish that fairly swiftly.
Larry Biegelsen
analystOkay. Thanks.
Steve Lichtman
analystThanks. Hello, everyone. John, wishing you the best of luck. It was a pleasure working with you. I just have a question about the fully closed loop. Could you share any further details on what the pivotal trial is going to look like, and when you do start it — if that happens by the end of this year — what the potential timing would be for approval of that enhanced algorithm?
John Sheridan
executiveYes. Let me say right at the start that we're highly confident we'll kick it off in the fourth quarter. It's going to be a big study. It will include type 1 and type 2 as well as adolescents; it's going to involve more than 300, perhaps even 400 400 people. My understanding is that every participant will need to go through 3 months. Right now we're in the midst of contracting and getting patients prepared to start the study; it usually takes us 3 to 4 quarters to get through it. We'd expect to have sufficient data by the end of 2027 to submit to the FDA. That review process probably takes a quarter or 2, so I'd say that in 2028, we'd expect the product to be on the market; we're very excited about it; we believe we've got the best product that's coming to market. Our relationship with UVA is great. They've developed a really nice product, and we're really excited about it. As I said, we think this is going to be a game changer for the business.
Steve Lichtman
analystThank you, John.
Jacob Malaynik
analystHello, everyone. Appreciate you taking the questions, and congratulations to John. Turning to the acceleration of international growth, you mentioned that going direct delivers at least the 30% pricing uplift along with the renewal opportunity; in the markets you've already transitioned, could you break out the contribution from patient demand, pricing, and possibly catch-up shipments after the infusion set constraints? And then, how much of the quarter's growth reflects what you'd call the underlying trajectory for next year?
Leigh Vosseller
executiveAbsolutely. Those are great questions. From the international standpoint, I think you framed it well — the items that were drivers; in the third quarter specifically, we did see a modest deferral of sales out of the second quarter tied to supply shipments, which benefited the quarter. The largest drivers, I'd say, were the new products, with Mobi scaling up in its launch and AutoSoft Plus also launching, where distributors were placing some of their initial stocking orders for that product. Looking at the strength, direct markets remain a small share of the business as of the end of the third quarter. By the time we reach the end of the year, we should be serving roughly 30% of our base in those direct markets. Even though the contribution is small right now, the progress there is quite exciting. Shipments in those markets rose 30% from Q2 to Q3, and we're only in the earliest phases there. Overall, without attaching any hard numbers, there was contribution from both that volume increase in the direct and distributor markets — but notably in the direct markets — as well as the pricing benefit we capture from that uplift from being direct, and then the new products just beginning to build more momentum. International markets, at least for Tandem, have been underappreciated by many, I believe, and I think you'll start to see some genuinely exciting things happen there as we continue along this journey.
John Sheridan
executiveOne more thing I'd mention: early numbers show Mobi performing extremely strongly abroad. I'm quite enthusiastic about the way that will push the growth even further.
Jacob Malaynik
analystThank you.
Leigh Vosseller
executiveSure. There's a lot of positive material there regarding pharmacy and adoption. Perhaps I can address a handful of the factors we believe will affect or aid pharmacy adoption in the near term. A portion of that is simply the early lessons from working through the implementation, how the processes function, educating physicians; we've now reached a coverage level where we can begin marketing more broadly to the pharmacy channel. All of those are areas where we can start building that momentum. Coverage stands at a really solid level, and we anticipate continuing to see expanded coverage by the time Mobi becomes fully available commercially. Mobi Tubeless is helping push that coverage conversation, but also, with availability only in the pharmacy, it will help drive that volume through pharmacy. We view that not as a restriction for people but as a momentum builder, and it will keep lifting us to the coverage level where we won't have this gap for people lacking immediate access. As John mentioned earlier, people can purchase their pump today, and they can move to tubeless supplies at any future date; we believe this will generate a lot of positive momentum for Mobi itself as a platform, and we do believe this actually will be a major help to our pharmacy, meeting our pharmacy goals.
Ravi Misra
analystHi there, good afternoon. John, congratulations. This is Ravi speaking on behalf of Rich. I simply wanted to probe a little on the FCL and the larger-picture matter regarding how you expect this to land with payers. Clearly, you're still battling for coverage in that channel, but over the longer term, could you just help me grasp — everybody has one of these algorithms launching in a couple of years or so — is it basically something you have to be part of the payer conversations about, or is it something where, obviously, you can't make the merits argument just yet? Just give us a bit of insight into how that strategy looks there. Thank you.
John Sheridan
executiveSure. My view is that fully closed loop is going to let patients achieve the same outcomes, or perhaps even better ones, than what we see today with hybrid closed loop systems, minus the effort that comes with it. Those who prefer to just set it and forget it are able to do so. For those individuals, that represents a meaningful decrease in the diabetes burden. As you consider AID system uptake, in the early days you had the early adopters who might be willing to engage with the system — perhaps a bit more technical interaction with the system is required. As we progress along the growth curve, the people we're engaging with at present, including those with type 2 especially, are looking for a very simple experience. In my view, making the experience of wearing a device 24/7 simpler is truly, truly essential, and I believe it's among the primary forces behind lifting adoption rates to 65% plus, given that we're currently at around 40. Once more, I think the experience people will have is going to be genuinely positive, and it will unquestionably propel adoption for both type 1 and type 2 people living with diabetes.
John Block
analystGreat. Thanks, guys. Good afternoon. Leigh, maybe I'm getting something wrong here, but from what you said earlier it looks like around 10,000 pumps could now be flowing through pharmacy — I believe you mentioned 10% to 12% of the 94, 95,000, compared with the 18,000 originally planned, which was 20% of the 94, 95,000. If an additional 8,000 pumps are going through DME and the upfront ASP, does that put you at $32 million that you're now receiving upfront on the pump side? I realize you're giving up something on the supplies, but it's late in the year, so you're not giving up many months on the supplies. Why is the overall guide unchanged? Why isn't that showing up already, now that you've got more upfront dollars going into the pump side? Thanks.
Leigh Vosseller
executiveYeah. That's a fair question. As we think about the variables for this year, guidance always has a bunch of factors baked into it, right? You've got to consider the market, the competition, growth rates, all those usual elements. With pharmacy, it gets even more complicated given all the variables involved there. As we looked at it, our thinking is that we're very focused on the pharmacy adoption piece, and so if we push more volume through pharmacy, say, well, first off, that's a larger headwind on sales. Should it end up as DME rather than pharmacy, that would represent an opportunity for additional revenue, if you want to frame it that way. At present, we chose to lean toward the possibility that stronger-than-expected pharmacy performance might actually hurt sales, so we intend to watch how these patterns develop through the quarter's close. Getting the revenue figure right matters more to us, and the levers for reaching it are what we'll continue to work on as we receive additional trends and data from the pharmacy side. Right now, what we're keeping our eye on is this: for Q4, we expect somewhere between 15% and 20% of shipments to go through the pharmacy channel, and that kind of drag is going to persist — that's already baked into the guidance we've given.
John Block
analystThanks.
Mike Kratky
analystHey there, everybody. Appreciate you taking our questions. John, congratulations on retiring. It was great working with you, and I hope we'll run into each other on the golf course at some point. Do you have any early thoughts, or how are you viewing the building blocks for 2027? If I'm reading it correctly, FactSet consensus appears to point to roughly 12% top-line growth next year. Does that seem about right, or with the pharmacy ramp recalibrated, would it be fair to assume something nearer to high single digits as a starting point, simply because that ASP uplift won't be there later in the year?
Leigh Vosseller
executiveThat's a really good question. You likely know that my usual response right now would be that it's too soon to provide figures. Given the modifications we outlined today regarding pharmacy and how quickly they're being taken up, I really believe it matters that we set people off on the correct footing. As I said in answer to the previous question, we'd rather lean toward the possibility that pump adoption moves faster than supply adoption takes hold—that persistent headwind everyone recognizes is approaching and that we're genuinely eager for—so we want to be sure we don't fall short on the revenue side. Your estimate is roughly right—a year-over-year rise in the mid-to-high single digits is likely a very reasonable baseline, since we're still collecting additional data and trends during Q4 and the start of Q1 ahead of our year-end earnings call. That's how I'd suggest framing it. One more point I'd emphasize: this isn't solely a matter of the revenue growth percentage. We've demonstrated this year that the business can deliver strong results — growth in new starts, gains in market share — while those other elements stay highly competitive, particularly as we prepare to compete next year in the pump market's fastest-growing segment. Many positive developments are underway in the business, yet the pharmacy transition carries that structural impact on revenue, which is likely a lot of discussion points around a sensible starting place.
Mike Kratky
analystGot it on that front. Perhaps just a single follow-up, though hearing you mention the return to growth in US new customer starts this quarter struck me as really encouraging. Could you perhaps clarify how big that was in 3Q, and what you've observed in 4Q so far that reinforces your confidence in the overall figure?
Leigh Vosseller
executivePerhaps I'll begin with the backward glance. New starts have faced pressure, and I believe the middle of last year, 2025, marked when new starts felt the heaviest pressure, and we've watched that improve steadily. In the prior quarter, we were right at the edge of breaking even; in this quarter, growth did come back. Beneath that, the primary force would be the MDI conversions. That's where we see the biggest impact, especially from Mobi. Once more, we believe Mobi Tubeless will act as a catalyst for the business in numerous ways, whether that's simply new pumpers arriving at Tandem, or pharmacy adoption. MDI have climbed to roughly 70% of pump shipments; as a matter of fact, this quarter, MDI rose by almost 10%. That's a genuinely favorable trend for us, and we're eager to keep driving it as we head into next year.
Mike Kratky
analystGot it. Many thanks.
John Sheridan
executiveTubeless Mobi, pharma, and FreeStyle Libre all strike me as clear tailwinds that will genuinely help us capitalize on the type 2 market. C-peptide is a genuine issue; even so, our outlook is quite positive. We're quite confident this will get resolved; we're awaiting decisions from CMS. In my view it's not a question of if but of when. Certainly, we had expected this to occur around the August time frame. My guess is the election has probably interfered. We're hoping to hear something on this before long. I believe it's a really significant step forward for people with type 2, and we look forward to seeing that take place. Thank you.
Matt Taylor
analystHi, thanks for taking my question. John, congratulations. If you could just bring me along with you, please. Only joking. It was wonderful working with you, and
John Sheridan
executiveI was sure I'd locate you in... I know where you can be found, man.
Matt Taylor
analystYes, that's correct. Perhaps I could pose a broader question about market expansion. We've seen robust market growth in this area for several years now. There's a great deal of innovation originating from your company and throughout the industry. I'm curious whether you believe this is sufficient to speed up market growth, or merely to maintain the growth we're observing over the coming couple of years? Maybe I could just hear your perspective on that.
John Sheridan
executiveIt's always hard to sort of figure out how things are going partway through the year. I'd simply note that, reflecting on '25, I believe every one of the pump companies performed rather well. At the close of '25, penetration may have stood at a high 30s, perhaps 40%. Our view is that it can reach 65%. A tremendous opportunity still exists for us in that space. I think your point is valid. Innovation, in my view, fuels adoption. Simplicity of use fuels adoption. Everyone is moving in that direction; not just our rivals, but our partners too. What this accomplishes, I believe, is that it truly delivers excellent technology to assist individuals living with diabetes, and we are part of that effort. I genuinely believe the technology is excellent, and it will keep generating fresh growth possibilities within this market.
Matt Taylor
analystThanks so much.
Jeff Johnson
analystThank you. Good evening, guys. John, I'll throw my congrats out there as well. As I've said to a couple of CEOs retiring, I'm jealous at the stage of my career that you're making the jump. Good luck in that.
John Sheridan
executiveThanks, Jeff.
Jeff Johnson
analystYeah. I've been hopping between calls here. If somebody already raised this question, just let me know and I'll check the transcript later. No point spending time answering it again. On the AID-NET trial, I'm fairly certain you're taking a bolus-optional approach, where bolusing at mealtime is either possible or not, and it's largely up to the user. Maybe just share your thinking on why keeping a bolus-optional choice matters, particularly in type 1, versus moving toward a more fully forced closed loop, as some of your peers may be doing in either type 1 or type 2. Thanks.
John Sheridan
executiveWhat I'd say is that we haven't stated that yet. What we have stated, though, is that people will be permitted to make adjustments to the system so as to optimize how it performs. I think our belief is that it will be fully closed loop, with the capability to adjust the system should you wish to optimize performance; we have not mentioned a bolus-optional at this point in time. I think that as time goes on, we'll get more specific about some of the particular features we intend to bring to market.
Jeff Johnson
analystAt mealtime, do you broadly think it matters for someone with type 1 to have the option to announce they're eating — and if they choose not to, perhaps they simply accept a somewhat lower time in range? I suppose, as you work through that decision tree and consider the pivotal trial and then how you'll eventually commercialize the system, what's your overall view on that?
John Sheridan
executiveOur aim is for the system to deliver the best performance. We want to see people achieve the highest time in range and the greatest A1C reduction. We are certainly assessing — and have assessed — a range of features along those lines, but as I mentioned, we have not been specific about which ones will make up that final feature set that will begin in the fourth quarter with our clinical study.
Jeff Johnson
analystThank you.
John Sheridan
executiveYep.
John Sheridan
executiveAll right, since this marks the last earnings call I’ll be on as CEO, I wanted to repeat how much of a privilege it has been to head Tandem and to serve with such a remarkable team. Everything we have achieved together makes me proud, and my confidence in what lies ahead for the company is very strong. Thank you for backing us throughout the years, and thank you for being on today’s call.
Operator
operatorThank you for your participation. You may now disconnect. Good day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tandem Diabetes Care, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Tandem Diabetes Care, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tandem Diabetes Care, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.